8-K: N2OFF Completes MitoCareX Acquisition, Enters Biotech

N2OFF, a cleantech company, has finalized its acquisition of MitoCareX Bio Ltd., marking its entry into the drug discovery market for resistant cancers.

Summary

• N2OFF, Inc. completed the acquisition of MitoCareX Bio Ltd. on October 20, 2025, making MitoCareX a wholly-owned subsidiary.
• MitoCareX is a biotech company focused on drug discovery for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting mitochondrial SLC25 proteins.
• Consideration for the acquisition included a $700,000 cash payment to SciSparc Ltd. and the issuance of N2OFF common stock representing 40% of N2OFF's fully diluted capital to the sellers.
• The sellers (SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri) received 490,751, 454,127, and 227,064 shares of N2OFF common stock, respectively.
• Sellers are also entitled to 30% of N2OFF's financing proceeds (capped at $1.6 million) for five years and milestone-based issuances of up to 25% of N2OFF common stock.
• N2OFF committed to financially support MitoCareX's operations for the first two years post-closing.

Sentiment

Score: 7

Explanation: The acquisition represents a significant strategic diversification into a high-growth market with proprietary technology. However, it involves substantial dilution, cash outlay, and ongoing financial commitments, alongside the inherent risks of drug discovery and integrating disparate business models.

Positives

• Entry into the potentially high-growth cancer therapeutics market, estimated at $211.02 billion in 2025 and projected to reach $378.62 billion by 2032 (8.7% CAGR).
• Diversification of N2OFF's business beyond cleantech and post-harvest treatments into a new, high-potential sector.
• Acquisition of proprietary technology, MITOLINE algorithm, for 3D comparative modeling of mitochondrial SLC25 proteins, aiding in anti-cancer small molecule discovery.

Negatives

• Significant cash outlay of $700,000 to SciSparc.
• Substantial dilution of existing N2OFF shareholders, with 40% of fully diluted capital stock issued to sellers at closing, plus potential future dilution of up to 25% based on milestones.
• Commitment to financially support MitoCareX's operations for two years post-closing, representing an ongoing financial obligation.
• Sellers are entitled to 30% of N2OFF's financing proceeds (capped at $1.6 million) for five years, potentially impacting future capital raises.

Risks

• Uncertainty regarding the successful implementation of potential synergies between N2OFF and MitoCareX.
• Operational and business opportunities available to N2OFF following the acquisition may not materialize as expected.
• The potential benefits MitoCareX can present to N2OFF may not be realized.
• Risks associated with N2OFF's existing solar PV sector business, including successful entry, profitability, and added value of increased capacity.
• General market conditions affecting N2OFF's business.
• Other risks detailed in N2OFF's Annual Report on Form 10-K filed on March 31, 2025.

Future Outlook

N2OFF anticipates potential synergies between its existing operations and MitoCareX, aiming to leverage new operational and business opportunities. The company expects potential benefits from MitoCareX's drug discovery platform and aims to successfully integrate into the solar PV sector, enhancing profitability and capacity value. Future financial statements for MitoCareX will be filed within 71 days.

Management Comments

• N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer.

Industry Context

This acquisition represents a significant strategic shift for N2OFF, moving from its core cleantech and agricultural technology businesses into the high-growth biotechnology sector, specifically drug discovery for oncology. The cancer therapeutics market is projected for substantial growth, indicating a strategic move into a potentially lucrative, albeit high-risk, industry. This diversification could position N2OFF to capitalize on different market dynamics compared to its existing solar energy and food preservation ventures.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• SciSparc Ltd. is a seller in the acquisition and received $700,000 cash and N2OFF common stock.
• Mr. Amitay Weiss, N2OFF's Chairman, also serves as Chairman of SciSparc.
• Ms. Liat Sidi, an N2OFF Board member, also serves as a Board member of SciSparc.

Stakeholder Impact

• Shareholders: Significant dilution (40% at closing, with potential for up to 25% more for milestones) and potential future claims on financing proceeds. Potential for long-term value creation through diversification into biotech.
• Employees: MitoCareX employees are now part of N2OFF. N2OFF employees may see a shift in company focus and resources.
• Customers/Suppliers: No direct immediate impact mentioned for existing cleantech or Save Foods customers/suppliers. New relationships will form for MitoCareX.
• Creditors: N2OFF's financial commitments (cash payment, operational support, financing proceeds share) could impact its financial structure and credit profile.

Next Steps

• N2OFF will file audited financial statements of MitoCareX Bio Ltd. and unaudited pro forma condensed combined financial information within 71 calendar days.
• N2OFF is committed to financially supporting MitoCareX's operations for the first two years following the closing.
• Potential future milestone-based issuances of N2OFF common stock to sellers.
• Potential future financing activities where sellers are entitled to a portion of proceeds.

Key Dates

Recommendation

The acquisition of MitoCareX represents a bold strategic pivot for N2OFF into the high-growth biotech sector, offering significant long-term potential in cancer therapeutics. However, the immediate impact includes substantial shareholder dilution (40% at closing, with potential for more), a notable cash outlay, and ongoing financial commitments to support the acquired entity. The inherent risks of drug discovery, coupled with the challenge of integrating a biotech company into a cleantech and agritech portfolio, warrant a cautious 'hold' stance. Investors should monitor the integration process, the progress of MitoCareX's drug development pipeline, and N2OFF's ability to manage its diversified portfolio effectively before considering further investment.

Keywords

N2OFF, MitoCareX, Acquisition, Biotech, Drug Discovery, Cancer Therapeutics, Pancreatic Cancer, Non-Small Cell Lung Cancer, SLC25 protein, MITOLINE, Cleantech, Solar Energy, Save Foods, Merger, NASDAQ: NITO